Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Huober

Showing results (1-10 of 221) with videos related to

Pageof 23
Sort By:
Zentralblatt Fur Gynakologie|July 4, 2006
[Adjuvant therapy with trastuzumab in primary breast neoplasms--findings and validity of--opinion on the competence of the Central Oncology section of the North German Society]Jens Huober
Cancers|August 26, 2023
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and PerspectivesInga Bekes, Jens Huober
Critical Reviews in Oncology/Hematology|April 30, 2010
Bone targeted therapy in breast cancer: present and futureJens Huober, Beat Thürlimann
Therapeutische Umschau. Revue Therapeutique|July 16, 2008
[Adjuvant endocrine therapy in breast cancer]Jens Huober, Beat Thürlimann
Breast Care (Basel, Switzerland)|March 12, 2015
Bone targeted therapy in breast cancer - an old concept but still much to doJens Huober, Beat Thürlimann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Diagnostic and prognostic use of bone turnover markersMarkus Joerger, Jens Huober
Breast Care (Basel, Switzerland)|September 30, 2010
The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast CancerJens Huober, Beat Thürlimann
Breast Care (Basel, Switzerland)|March 16, 2012
Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?Jens Huober, Gunter von Minckwitz
Therapeutische Umschau. Revue Therapeutique|July 16, 2008
[New treatment approaches in breast cancer]Christian Spirig, Beat Thürlimann, Jens Huober
JAMA Oncology|February 8, 2024
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-ReplyJens Huober, Beat Thürlimann, Daniel Dietrich
Pageof 23

Showing results (1-10 of 221) with videos related to

Sort By:
Pageof 23
Zentralblatt Fur Gynakologie|July 4, 2006
[Adjuvant therapy with trastuzumab in primary breast neoplasms--findings and validity of--opinion on the competence of the Central Oncology section of the North German Society]Jens Huober
Cancers|August 26, 2023
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and PerspectivesInga Bekes, Jens Huober
Critical Reviews in Oncology/Hematology|April 30, 2010
Bone targeted therapy in breast cancer: present and futureJens Huober, Beat Thürlimann
Therapeutische Umschau. Revue Therapeutique|July 16, 2008
[Adjuvant endocrine therapy in breast cancer]Jens Huober, Beat Thürlimann
Breast Care (Basel, Switzerland)|March 12, 2015
Bone targeted therapy in breast cancer - an old concept but still much to doJens Huober, Beat Thürlimann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Diagnostic and prognostic use of bone turnover markersMarkus Joerger, Jens Huober
Breast Care (Basel, Switzerland)|September 30, 2010
The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast CancerJens Huober, Beat Thürlimann
Breast Care (Basel, Switzerland)|March 16, 2012
Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?Jens Huober, Gunter von Minckwitz
Therapeutische Umschau. Revue Therapeutique|July 16, 2008
[New treatment approaches in breast cancer]Christian Spirig, Beat Thürlimann, Jens Huober
JAMA Oncology|February 8, 2024
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-ReplyJens Huober, Beat Thürlimann, Daniel Dietrich
Pageof 23